2 weeks Ago By Defense World Staff
Prudential Financial Inc. trimmed its holdings in shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) by 7.
4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,335 shares of the company’s stock after selling 5,800 shares during the quarter. Prudential Financial Inc.
owned 0.28% of Tourmaline Bio worth $1,467,000 at the end of the most recent quarter. Other hedge funds have also bought and sold shares of the company.
Brooklyn Investment Group bought a new position in Tourmaline Bio in the 4th quarter valued at $32,000. KLP Kapitalforvaltning AS bought a new position in Tourmaline Bio during the fourth quarter valued at about $47,000. The Manufacturers Life Insurance Company purchased a new stake in Tourmaline Bio during the third quarter worth about $226,000.
MetLife Investment Management LLC bought a new stake in Tourmaline Bio in the third quarter worth about $357,000. Finally, JPMorgan Chase & Co. grew its position in shares of Tourmaline Bio by 16.
5% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company’s stock valued at $381,000 after acquiring an additional 2,100 shares during the period.
91.89% of the stock is currently owned by institutional investors. Tourmaline Bio Stock PerformanceNASDAQ:TRML opened at $12.
83 on Friday. Tourmaline Bio, Inc. has a 52-week low of $11.
87 and a 52-week high of $29.79. The stock has a fifty day moving average of $14.
87 and a 200 day moving average of $20.70. The firm has a market capitalization of $329.
54 million, a price-to-earnings ratio of -4.55 and a beta of 2.35.
Tourmaline Bio (NASDAQ:TRML – Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.
91) by $0.05. The business had revenue of $0.
04 million for the quarter. Equities analysts forecast that Tourmaline Bio, Inc. will post -3.
02 earnings per share for the current fiscal year. Wall Street Analyst Weigh InTRML has been the topic of a number of research reports. Guggenheim reaffirmed a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th.
Lifesci Capital started coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an “outperform” rating and a $58.00 price target on the stock.
Wedbush lifted their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Friday, March 14th.
Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, HC Wainwright boosted their price target on shares of Tourmaline Bio from $49.
00 to $50.00 and gave the company a “buy” rating in a research report on Friday, March 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $45.
20.View Our Latest Report on TRMLTourmaline Bio Profile (Free Report)Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Featured StoriesFive stocks we like better than Tourmaline BioTrading Stocks: RSI and Why it’s UsefulConagra Stock Could Thrive as Tariffs Hit Other SectorsThe 3 Best Fintech Stocks to Buy NowGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsInvesting in Commodities: What Are They? How to Invest in ThemSpotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?.
